CoChat

Monitoring Cholesterol Levels: Measurement Error or True Change?

Glasziou, Paul P., Irwig, Les, Heritier, Stephane, Simes, R. John, Tonkin, Andrew, for the LIPID Study Investigators · 2008 · Annals of Internal Medicine
Cited by 122

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Cholesterol level monitoring is a common clinical activity, but the optimal monitoring interval is unknown and practice varies. OBJECTIVE: To estimate, in patients receiving cholesterol-lowering medication, the variation in initial response to treatment, the long-term drift from initial response, and the detectability of long-term changes in on-treatment cholesterol level ("signal") given short-term, within-person variation ("noise"). DESIGN: Analysis of cholesterol measurement data in the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) study. SETTING: Randomized, placebo-controlled trial in Australia and New Zealand (June 1990 to May 1997). PATIENTS: 9014 patients with past coronary heart disease who were randomly assigned to receive pravastatin or placebo. MEASUREMENTS: Serial cholesterol concentrations at randomization, 6 months, and 12 months, and then annually to 5 years. RESULTS: Both the placebo and pravastatin groups showed small increases in within-person variability over time. The estimated within-person SD increased from 0.40 mmol/L (15 mg/dL) (coefficient of variation, 7%) to 0.60 mmol/L (23 mg/dL) (coefficient of variation, 11%), but it took almost 4 years for the long-term variation to exceed the short-term variation. This slow increase in variation and the modest increase in mean cholesterol level, about 2% per year, suggest that most of the variation in the study is due to short-term biological and analytic variability. Our calculations suggest that, for patients with levels that are 0.5 mmol/L or more (> or =19 mg/dL) under target, monitoring is likely to detect many more false-positive results than true-positive results for at least the first 3 years after treatment has commenced. LIMITATIONS: Patients may respond differently to agents other than pravastatin. Future values for nonadherent patients were imputed. CONCLUSION: The signal-noise ratio in cholesterol level monitoring is weak. The signal of a small increase in cholesterol level is difficult to detect against the background of a short-term variability of 7%. In annual rechecks in adherent patients, many apparent increases in cholesterol level may be false positive. Independent of the office visit schedule, the interval for monitoring patients who are receiving stable cholesterol-lowering treatment could be lengthened.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-148-9-200805060-00005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 122

Metadata

Authors
Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & for the LIPID Study Investigators
Venue
Annals of Internal Medicine
Published
2008-05-06
Volume
148
Issue
9
Pages
656-661
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2097618561
Cited by
122
References
4
FWCI
11.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monitoring Cholesterol Levels: Measurement Error or True Change? https://app.cochat.ai/papers/10.7326/0003-4819-148-9-200805060-00005
The paper
Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & for the LIPID Study Investigators. (2008). Monitoring Cholesterol Levels: Measurement Error or True Change? Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-148-9-200805060-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.